IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk? - Wikidata - awgldk - TriplyDB

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

http://www.wikidata.org/entity/Q41104626

about

Management of cardiovascular disease in patients with psoriasis.Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling.Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

P2860

Q30250278-3B8A5421-B044-4B8A-8507-B5E74DA23D12 Q38701290-3DB97BE9-FEEF-4827-AAA6-15B26EDD0A76 Q46180528-10730097-DCA6-4BD4-9914-D5FBEB7AE881

P2860

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

http://www.wikidata.org/entity/Q41104626

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

@en

type

label

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

@en

prefLabel

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

@en

P1433

Q41104626-E158590B-9B09-4789-BB4D-3AB018EE32DC

P1476

Q41104626-7F37B19A-85E3-4106-BDA1-6934240157D4

P2093

Q41104626-320CA82F-5CFC-49ED-BB32-D8C03A8B8AB2

Q41104626-F7726FB4-6C36-475F-A806-45DAE27B3AFF

P2860

Q41104626-09539D23-3A79-46CE-8175-13472D91E2BB

Q41104626-0BADCB48-C707-4398-82D7-CC1A2257BADA

Q41104626-0E463670-EF87-43F1-9307-EB213397274A

Q41104626-1E6015CF-A30C-47DC-946E-E7BBCED4D419

Q41104626-25CB589C-79DB-4BB6-A2DB-8C551C2F18FE

Q41104626-30C08560-18FC-4EEE-B66F-85A6299E0673

Q41104626-31BB64CC-9B4D-41BF-935E-22CD71F80601

Q41104626-384B983D-3586-49F0-B860-479965505FB4

Q41104626-45486A0A-42E9-4CFE-9E4A-92614D3FD300

Q41104626-506ADBF9-8434-4C70-A1AA-11BD12637E67

P2888

Q41104626-E4819C81-EAE6-46DA-AC67-0F23A3114AAC

P304

Q41104626-705B8257-DDE4-4AD2-A341-5D415CE0DA9C

P31

Q41104626-B85EDFF6-E9DF-47D8-B2AF-6A6FD8207BFA

P356

Q41104626-7B0A8C2E-DDA0-4018-A50E-6E79D6E4984F

P433

Q41104626-3088E890-91F0-4F9A-A86F-FA90DBC0C13F

P478

Q41104626-46768CD7-DE7A-40FA-AD1C-25ADDE49E7D1

P50

Q41104626-A20002AA-D987-45CB-8B1D-AB7A45C304F3

P577

Q41104626-1E48FBBD-D1CC-41CE-B4E6-BA910B8F7E90

P698

Q41104626-969A37CD-2CF6-45FA-B279-E7D57CAA68F8

P356

S40257-015-0166-0

P1433

American Journal of Clinical Dermatology

P1476

IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?

@en

P2093

Inês Raposo

http://www.w3.org/2001/XMLSchema#string

Manuela Selores

http://www.w3.org/2001/XMLSchema#string

P2860

Fate mapping of IL-17-producing T cells in inflammatory responses

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.

Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.

γδT cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice.

IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.

Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.

Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.

Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses.

TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

P2888

s40257-015-0166-0

P304

107-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40257-015-0166-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26596991

http://www.w3.org/2001/XMLSchema#string